Abstract: A method of regulating pain in a patient includes operations of measuring a patient pain level, determining a dose of ethanol which does not trigger alcohol intolerance or intoxication, delivering the dose of ethanol to the patient by inhalation from an active mesh nebulizer at a repeated interval, measuring the pain level of the patient at a monitoring interval, and determining, based on the patient pain level, whether to adjust the ethanol dose. The dose of ethanol is delivered in the form of particles of nebulized liquid having a diameter ranging from about 0.5 ?m to about 5.0 ?m, which are rapidly absorbed into the bloodstream of a patient and delivered to the brain.

Abstract: A method of regulating pain in a patient includes operations of measuring a patient pain level, determining a dose of ethanol which does not trigger alcohol intolerance or intoxication, delivering the dose of ethanol to the patient by inhalation from an active mesh nebulizer at a repeated interval, measuring the pain level of the patient at a monitoring interval, and determining, based on the patient pain level, whether to adjust the ethanol dose. The dose of ethanol is delivered in the form of particles of nebulized liquid having a diameter ranging from about 0.5 ?m to about 5.0 ?m, which are rapidly absorbed into the bloodstream of a patient and delivered to the brain.

Abstract: A treatment for symptoms of migraine and cluster headaches includes operations of providing a solution of a serotonin receptor agonist (SRA) in an active mesh nebulizer, triggering the formation of a plume of particles from the active mesh nebulizer, and delivery of the plume of particles into the lungs of a patient during an inhalation process.

Abstract: A method of treating respiratory system tissue, includes operations of generating a plume of particles of a treating solution from a nebulizer, inhaling particles of the treating solution, delaying exhalation of an inhalation having particles of the treating solution therein, and determining whether a dose of the treating solution has been delivered, wherein the treating solution is a solution of at least 40% ethyl alcohol, by volume.

Abstract: A method of delivering a medication or a pharmaceutical product to a patient includes operations of activating an active mesh of an active mesh nebulizer, the active mesh being in contact with a liquid formulation of the medication, and configured to generate a plume of particles having a particle diameter between 1 and 6 micrometers, directing the plume of particles to a mouth of a patient during an inhalation by a patient; and stopping the plume of particles during the inhalation by the patient such that a substantial majority, or nearly all, of the plume of particles is inhaled by the patient.

Abstract: A method of regulating weight in a patient includes operations of measuring a patient weight, determining a dose of nicotine which does not trigger nicotine intolerance, delivering the dose of nicotine to the patient by inhalation from an active mesh nebulizer at a repeated interval, measuring the weight of the patient at a weight monitoring interval, and determining, based on the patient weight and patient behavior, whether to adjust the nicotine dose.

Abstract: A method of using a nebulizer includes connecting a medicine vial containing a medicine solution to the nebulizer and reading a medicine conductivity and/or pH value from the medicine vial. The conductivity and/or pH of the medicine solution is measured and compared with the medicine conductivity and/or pH value. When the medicine conductivity and/or pH value and the measured conductivity and/or pH of the medicine solution match, the flow rate value and dosage timings are read from the medicine vial; and the mesh is activated at the medicine flow rate value to produce a plume of particles of a medicine solution at the beginning of an inhalation. The active mesh is deactivated to stop making particles by manually or at a calculated time. The activation of the active mesh is restricted to approved users by means of an authentication code or biometric feature information.

Abstract: A treatment for symptoms of migraine and cluster headaches includes operations of providing a solution of a serotonin receptor agonist (SRA) in an active mesh nebulizer, triggering the formation of a plume of particles from the active mesh nebulizer, and delivery of the plume of particles into the lungs of a patient during an inhalation process.

Abstract: A method of treating respiratory system tissue, includes operations of generating a plume of particles of a treating solution from a nebulizer, inhaling particles of the treating solution, delaying exhalation of an inhalation having particles of the treating solution therein, and determining whether a dose of the treating solution has been delivered, wherein the treating solution is a solution of at least 40% ethyl alcohol, by volume.

Abstract: An endotracheal tube sound device is presented having a sound bead connected to the distal end of a wire. A retaining piece is affixed to the wire adjacent to the sound bead. A handle is connected to the proximal end of the wire. Using this device, the sound bead may be inserted into an endotracheal tube to determine if the endotracheal tube is deformed and then removed from the endotracheal tube by pulling on the handle.

Abstract: A nebulizer with an active mesh configured to produce a plume of particles for treating medical conditions is activated by a dosage request by a user, produces a plume of particles, at least 95% of which have a diameter between about 0.5 and up to about 5 ?m, and tracks delivery of a pharmacological compound in the plume of particles of nebulized solution. The active mesh is configured to turn on, and turn off, during a single inhalation, and to provide a dose of pharmacological compound over at least one inhalation of at least one plume. The active mesh does not produce a plume of particles when no inhalation occurs, to prevent waste and to ensure accurate dosing of pharmacological compound. The nebulizer blocks use of the active mesh when a dosage limit is met, and enables use of the active mesh when a dosing delay time has passed.

Abstract: A method of delivering a medication or a pharmaceutical product to a patient includes operations of activating an active mesh of an active mesh nebulizer, the active mesh being in contact with a liquid formulation of the medication, and configured to generate a plume of particles having a particle diameter between 1 and 6 micrometers, directing the plume of particles to a mouth of a patient during an inhalation by a patient; and stopping the plume of particles during the inhalation by the patient such that a substantial majority, or nearly all, of the plume of particles is inhaled by the patient.

Abstract: An aqueous nicotine solution for use in an active mesh nebulizer as part of a smoking cessation program, or as a substitute for tobacco use, includes nicotine in water with a nicotine concentration ranging from about 1.0 milligram (mg) nicotine per milliliter (ml) of water (e.g., 0.01% nicotine), to about 0.005 mg nicotine per milliliter of water (about 0.0005% nicotine). The pH of the aqueous nicotine solution ranges from about 3.5 to about 12 because the plume of particles of aqueous nicotine solution produced by the active mesh nebulizer are entrained with the inhaled air and do not impact the walls of the throat or lungs. The aqueous nicotine solution is free from metals because it is delivered to a user at room temperature, without heating or boiling.

Abstract: An active mesh nebulizer is used to generate a distribution of liquid particles or droplets having a diameter ranging from about 0.5 to about 5 micrometers (?m). Delivery and ingestion, by inhalation, of ethyl alcohol solution particles leads to rapid uptake of the alcohol solution by brain tissue, and avoids damage to the liver, gastrointestinal tract, and/or peripheral nervous system consistent with drinking ethyl alcohol. A brain effect of ethyl alcohol absorbed through alveoli in the lung occurs within less than 60 seconds, and body effects of alcohol consumption are reduced or eliminated. Delivery of ethyl alcohol to a user by absorption through alveoli provides a user with a brain effect while allowing tissue damage from drinking alcohol to heal. A lock out barcoded capsule containing ethyl alcohol, tethered to a smartphone application, prevents unauthorized use by non-designated users, or abuse by a designated user.

Abstract: An active mesh nebulizer is used to generate a distribution of liquid particles or droplets having a diameter ranging from about 0.5 to about 5 micrometers (?m). Delivery and ingestion, by inhalation, of ethyl alcohol solution particles leads to rapid uptake of the alcohol solution by brain tissue, and avoids damage to the liver, gastrointestinal tract, and/or peripheral nervous system consistent with drinking ethyl alcohol. A brain effect of ethyl alcohol absorbed through alveoli in the lung occurs within less than 60 seconds, and body effects of alcohol consumption are reduced or eliminated. Delivery of ethyl alcohol to a user by absorption through alveoli provides a user with a brain effect while allowing tissue damage from drinking alcohol to heal. A lock out barcoded capsule containing ethyl alcohol, tethered to a smartphone application, prevents unauthorized use by non-designated users, or abuse by a designated user.

Abstract: In essence, the present invention relates to a medical product containing a normal saline solution and about 1/8th of 1 milligram and 3 milligrams of nicotine. The medical product may also include about 1% to 3% of flavor such as tobacco, menthol and hazelnut. The medical product may also include about 1 to 3 microns that are drawn through an entrainment port, a capsule, the grid and into the individual's lungs and their bloodstream. The present invention is also used for patients who want to maintain the benefits of nicotine such as alertness, memory retention, relaxation, maintaining normal bowel movement, and avoidance of weight gain, without the health risks of tobacco ingredients. It may also be used as a method to initiate weight loss in obese individuals as part of a plan including diet and exercise.

Abstract: A nebulizer comprising a nebulizing chamber with a vibrating mesh grid having a plurality of precision openings and said chamber with a liquid pharmaceutical product in a cartridge contacting the mesh grid for producing particle sizes of two (2) to four (4) microns; and an entrainment port for drawing air into the nebulizing chamber and through the grid. A control circuit, a source of electrical energy in said circuit such as two 1.5 volt lithium titanate batteries connected to said grid for producing vibration. A switch to turn said grid off and on and means for providing a first measured time period of four seconds for taking a first breath of air through the entrainment port and grid and through the thousands of passageways into the lungs and bloodstream of an individual. A second time period during which no vibration occurs. The grid is also self-cleaning as described.

Abstract: In essence, the present invention relates to a medical product including between about 94% and about 98% of a saline solution, preferably a normal saline solution containing about 0.9% sodium chloride dissolved in water, about ?th of 1 milligram of relatively pure nicotine and about 3 milligrams of relatively pure nicotine. The medical product also includes about 1% and 3% of one or more flavors selected from the group consisting of citrus, tobacco, apple, cherry, maple, menthol, hazelnut, peach, lemon, vanilla and chocolate and 1% citric acid for taste. In addition, the medical product includes about 1% to 2% of ethyl alcohol for cleaning a micron mesh grid that generates particles of pure nicotine of from 2 to 5 microns that are drawn through an entrainment port, through a capsule containing the medical product through the micron mesh grid and into the individual's lungs and into their bloodstream.

Abstract: In essence, the present invention relates to a medical product including between about 94% and about 98% of a saline solution, preferably a normal saline solution containing about 0.9% sodium chloride dissolved in water, about ?th of 1 milligram of relatively pure nicotine and about 3 milligrams of relatively pure nicotine. The medical product also includes about 1% and 3% of one or more flavors selected from the group consisting of citrus, tobacco, apple, cherry, maple, menthol, hazelnut, peach, lemon, vanilla and chocolate and 1% citric acid for taste. In addition, the medical product includes about 1% to 2% of ethyl alcohol for cleaning a micron mesh grid that generates particles of pure nicotine of from 2 to 5 microns that are drawn through an entrainment port, through a capsule containing the medical product through the micron mesh grid and into the individual's lungs and into their bloodstream.